Remibrutinib reduces relapse rates versus teriflunomide in Phase 3 MS trials REMODEL-1 and REMODEL-2, with results presented ...

Jupiter Neurosciences doses first Parkinson's patient in JOTROL Phase 2a trial, testing whether enhanced resveratrol achieves ...

FDA approves Rhapsido (remibrutinib) for symptomatic dermographism, the first prescription treatment for adults with the ...

Ribo files EU Trial Application for RBD3133, an siRNA targeting INHBE for obesity treatment backed by human genetic evidence.

JAMA's 2026 editorial exposes how "pragmatic trial" has been stretched beyond recognition, threatening regulatory credibility ...

Rezdiffra shows consistent efficacy across common MASH genetic risk variants in Phase 3 analysis, addressing prescribing ...

Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...

Oculis to present licaminlimab data at AAO 2026 following year-end PREDICT-1 readout in genotype-selected dry eye patients.

Forward Therapeutics' FT2109 advances to Phase 2 after clearing Phase 1 with once-daily oral dosing and a supportive safety ...

Most sites undercharge on research-paid items because no one reconciles the sponsor budget against the charge master. Here is ...

Headlands Research Portland site marks 50 years of continuous Alzheimer's trials, contributing to every FDA-approved ...